The U.S. Preventive Services Task Force (USPSTF) has issued new recommendations governing the use of statins for primary prevention of cardiovascular disease (CVD) in patients age 40 to 75 years with no history of CVD and no signs or symptoms of it.

The research community is challenged to identify safe and effective treatments for early COVID-19 disease that patients can take at home. While monoclonal antibodies represent one option, the constant evolution of the coronavirus creates barriers.

Researchers at NYU Grossman School of Medicine say 86.6% of people living with opioid use disorder (OUD) in the United States are not receiving medications proven to reduce opioid overdoses, including methadone, buprenorphine, and extended-release naltrexone. Their study, published in International Journal of Drug Policy, looked at differences between new estimates of OUD prevalence and the use of medications for OUD (MOUD) at the national and state levels from 2010 to 2019.

Drug companies are asking for lofty prices for new medications coming to market, a Reuters analysis finds, often while disclosing little pricing information about the treatments.

A new study in The Journal of the American College of Cardiology predicts that millions more Americans will develop CVD over the next few decades.